Health Insurance Innovations, Inc. (NASDAQ:HIIQ) shares advanced 0.24% in last trading session and ended the day at $4.25. And its has a return on assets of -0.80%. Health Insurance Innovations, Inc. (NASDAQ:HIIQ) quarterly performance is 2.41%.
Health Insurance Innovations, Inc. (HII) (NASDAQ:HIIQ), will announce its third quarter 2015 financial results on Monday, November 9, 2015, after market close. The announcement will be followed by a live earnings conference call that same day at 5 p.m. Eastern time.
Sportsman’s Warehouse Holdings, Inc. (NASDAQ:SPWH) ended the last trading day at $11.76. Company weekly volatility is calculated as 4.65% and price to cash ratio as 823.40. Sportsman’s Warehouse Holdings, Inc. (NASDAQ:SPWH) showed a weekly performance of 9.29%.
Sportsman’s Warehouse Holdings, Inc. (Nasdaq:SPWH) announced that it will hold its quarterly conference call to discuss third quarter 2015 financial results on Thursday, November 19, 2015 at 4:30 p.m. Eastern Time.
Pfizer Inc. (NYSE:PFE) shares decreased -0.64% in last trading session and ended the day at $33.93. PFE Gross Margin is 81.30% and its has a return on assets of 5.40%. Pfizer Inc. (NYSE:PFE) quarterly performance is -3.27%.
Heat Biologics, Inc. (NASDAQ:HTBX) shares advanced 7.19% in last trading session and ended the day at $4.47. And its has a return on assets of -79.60%. Heat Biologics, Inc. (NASDAQ:HTBX) quarterly performance is -26.24%.
A Pfizer Inc. (NYSE:PFE) merger with Ireland-based Allergan (AGN.N), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent. Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling three years of financial data treating its “established products” division, which sells generic medicines, and its “innovative” patent-protected medicines unit, as if they were separate companies.
Heat Biologics (Nasdaq: HTBX) announced results from its Phase 1 trial to evaluate safety and immune response to HS-410 (vesigenurtacel-L), after standard of care Bacillus Calmette-Guérin (BCG), for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). HS-410 had a positive safety profile and was well-tolerated with no patients discontinuing the trial due to adverse events. Furthermore, no serious adverse events were reported, and 7 out of 10 patients had no documented recurrence of cancer >1 year after standard of care surgery. Significantly, 3 out of 4 patients with carcinoma in situ (CIS), the patient population least responsive to standard of care, did not recur.
Immune Design Corp. (NASDAQ:IMDZ) caters to the Healthcare space. Its weekly performance is 41.85%. On the last day of trading company shares ended up at $18.44. Immune Design Corp. (NASDAQ:IMDZ) distance from 50-day simple moving average (SMA50) is -4.97%.
Immune Design (Nasdaq:IMDZ), announced that it will report third quarter 2015 financial results after the close of U.S. financial markets on Thursday, November 12, 2015. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 12, 2015 to discuss the third quarter 2015 financial results and provide a corporate update.
Leave a Reply